Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tetrahydrofuran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL2812148 | 0.89 | ALDH1A1 (0.53) | ALDH1A1TSHR | |
| Tetrahydrofuran SCHEMBL218583 | 0.89 | ALDH1A1 (0.53) | ALDH1A1TSHR | |
| Dioxane SCHEMBL17698398 | 0.86 | ALDH1A1 (0.38) | ALDH1A1TSHR | |
| Alcohol SCHEMBL7807841 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TSHR | |
| Tetrahydrofuran SCHEMBL30232 | 0.86 | — | — | |
| Tetrahydrofuran SCHEMBL8412489 | 0.86 | ALDH1A1 (0.57) | ALDH1A1TSHR | |
| Tetrahydrofuran SCHEMBL10606207 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TSHR | |
| Alcohol SCHEMBL4270003 | 0.83 | ALDH1A1 (0.53) | ALDH1A1TSHR | |
| Alcohol SCHEMBL3138912 | 0.83 | ALDH1A1 (0.53) | ALDH1A1TSHR | |
| Tetrahydrofuran SCHEMBL241626 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1240380-C | Phase transfer catalyzed glycosidation of indolopyrrolocarbazoles | MERCK & CO INC (US) | 2006-02-08 | — | — | CN | disclosed |
| EP-1264836-B1 | Processes for the preparation of indolopyrrolocarbazole derivatives | BANYU PHARMA CO LTD (JP) | 2004-12-01 | — | — | EP | disclosed |
| CN-1482908-A | Phase transfer catalyzed glycosidation of an indolocarbazole | — | 2004-03-17 | — | — | CN | disclosed |
| US-20040024196-A1 | Phase transfer catalyzed glycosidation of an indolocarbazole | PETRILLO DANIEL E (US) | 2004-02-05 | — | — | US | disclosed |
| EP-0760375-B1 | ANTITUMOR INDOLOPYPROLOCARBAZOLE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1333826-A2 | PHASE TRANSFER CATALYZED GLYCOSIDATION OF AN INDOLOCARBAZOLE | Merck & Co., Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6555677-B2 | Preparing preferential compound; incubate sugar with activating agent, couple activated sugar with preferential compound, recover compound | MERCK & CO., INC. | 2003-04-29 | — | — | US | disclosed |
| EP-1264836-A1 | Processes for the preparation of indolopyrrolocarbazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-20020058803-A1 | Phase transfer catalyzed glycosidation of an indolocarbazole | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-16 | — | — | US | disclosed |
| WO-2002036601-A2 | PHASE TRANSFER CATALYZED GLYCOSIDATION OF AN INDOLOCARBAZOLE | MERCK & CO., INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| US-5922860-A | Antitumor indolopyrrolocarbazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| US-5804564-A | Antitumor indolopyrrolocarbazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-09-08 | — | — | US | disclosed |
| EP-0760375-A1 | ANTITUMOR INDOLOPYPROLOCARBAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024196-A1 | Phase transfer catalyzed glycosidation of an indolocarbazole | UGGT1, UGCG, GPI | ALDH1A1 779/4885TSHR 2347/4885 |
| US-20020058803-A1 | Phase transfer catalyzed glycosidation of an indolocarbazole | UGGT1, UGCG, GPI | ALDH1A1 779/4885TSHR 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.